Cosmo Pharmaceuticals N.V. (LON:0RGI)

Cosmo Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	182.27	266.79	92.78	102.09	65.07	60.95
Revenue	182.27	266.79	92.78	102.09	65.07	60.95
Revenue Growth (YoY)	-1.66%	187.55%	-9.12%	56.88%	6.77%	-2.47%
Cost of Revenue	47.78	45.36	39.34	40.49	32.98	27.62
Gross Profit	134.49	221.43	53.44	61.6	32.1	33.33
Selling, General & Admin	39.48	41.53	37.99	19.98	10.52	18.68
Research & Development	33.54	34.68	19.25	15.46	11.29	13.6
Other Operating Expenses	-7.24	-3.66	-1.92	-1.9	-0.82	-0.75
Operating Expenses	65.77	72.55	55.32	33.54	21	31.53
Operating Income	68.72	148.88	-1.88	28.06	11.1	1.81
Interest Expense	-0.09	-0.05	-8.53	-9.16	-8.99	-8.73
Interest & Investment Income	1.42	1.67	4.07	2.94	3.06	1.75
Earnings From Equity Investments	-	-	-	-	17.75	-4.94
Currency Exchange Gain (Loss)	-1.43	1.02	-1.36	2.76	2.24	-1.49
Other Non Operating Income (Expenses)	-0.07	-0.07	-0.12	-0.11	-0.48	-0.17
EBT Excluding Unusual Items	68.55	151.45	-7.81	24.49	24.68	-11.78
Gain (Loss) on Sale of Investments	3.6	1.92	1.33	-0.02	-0.68	-0.25
Gain (Loss) on Sale of Assets	-	-	-	-	-	4
Other Unusual Items	-	-	-	-	-	1.1
Pretax Income	72.15	153.37	-6.49	24.47	24	-6.93
Income Tax Expense	12.17	20.18	4.21	6.97	2.33	0.97
Earnings From Continuing Operations	59.98	133.19	-10.7	17.51	21.67	-7.9
Minority Interest in Earnings	0.01	0.05	-0.08	-0.28	-0	-
Net Income	59.99	133.24	-10.78	17.23	21.67	-7.9
Net Income to Common	59.99	133.24	-10.78	17.23	21.67	-7.9
Net Income Growth	1.73%	-	-	-20.52%	-	-
Shares Outstanding (Basic)	16	16	16	16	17	14
Shares Outstanding (Diluted)	16	16	16	16	17	14
Shares Change (YoY)	1.65%	1.94%	-1.95%	-2.83%	16.81%	-1.11%
EPS (Basic)	3.68	8.14	-0.67	1.05	1.29	-0.55
EPS (Diluted)	3.67	8.12	-0.67	1.05	1.28	-0.55
EPS Growth	0.09%	-	-	-18.20%	-	-
Free Cash Flow	67.76	157.86	19.36	28.71	7.12	8.87
Free Cash Flow Per Share	4.14	9.62	1.20	1.75	0.42	0.61
Dividend Per Share	2.050	2.050	2.000	1.050	0.950	-
Dividend Growth	2.50%	2.50%	90.48%	10.53%	-	-
Gross Margin	73.79%	83.00%	57.60%	60.34%	49.32%	54.69%
Operating Margin	37.70%	55.81%	-2.02%	27.48%	17.06%	2.96%
Profit Margin	32.91%	49.94%	-11.62%	16.87%	33.30%	-12.96%
Free Cash Flow Margin	37.17%	59.17%	20.87%	28.12%	10.95%	14.54%
EBITDA	80.45	160.47	9.27	41.17	17.81	6.06
EBITDA Margin	44.14%	60.15%	9.99%	40.33%	27.37%	9.94%
D&A For EBITDA	11.73	11.59	11.14	13.11	6.71	4.25
EBIT	68.72	148.88	-1.88	28.06	11.1	1.81
EBIT Margin	37.70%	55.81%	-2.02%	27.48%	17.06%	2.96%
Effective Tax Rate	16.87%	13.15%	-	28.47%	9.71%	-

Updated Jul 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.